WVE
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Wave Life Sciences reports FDA feedback supporting a registrational pathway for WVE-006, an RNA editing therapy for AATDOct 1, 2026
- Wave Life Sciences announces GSK's selection of an siRNA program for transition to GSK for further developmentSep 30, 2026
- Wave Life Sciences initiates a Phase 2a combination trial of WVE-007 GalNAc-siRNA with tirzepatide for obesitySep 23, 2026
- Wave Life Sciences initiated the Phase 2a portion of the INLIGHT trial evaluating WVE-007 for obesity and cardiometabolic diseasesJun 24, 2026
- Wave Life Sciences reports positive RestorAATion-2 update with WVE-006 achieving MZ-like phenotype across dosing schedulesMay 19, 2026